

Study of irisin hormone level in type 2 Diabetic patients and patients with diabetic Nephropathy

Thesis

Submitted for Partial Fulfilment of Master Degree in
Internal Medicine

BY

Yasmeen Abd Almageed Mohamed
M.B., B.CH.

Supervised by

Prof. Salah El Din Ahmed Abu Shelbaya

Professor of Internal Medicine & Endocrinology
Faculty of Medicine – Ain Shams University

Dr. Manal Mohammad Abu-Shady

Assistant Professor of Internal Medicine & Endocrinology
Faculty of Medicine – Ain Shams University

Dr. Merhan Sami Nasr

Lecturer of Internal Medicine & Endocrinology
Faculty of Medicine – Ain Shams University

**Faculty of Medicine
Ain Shams University**

2015

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

وَقَدْ أَعْمَلُوا فَسَيَرَى اللَّهُ عَمَلَكُمْ
وَرَسُولُهُ وَالْمُؤْمِنُونَ

صدق الله العظيم

سورة التوبة آية (١٠٥)



First of all, thanks to **God** for giving me the strength to complete this work.

I wish to express thanks and respect for **Prof. Salah El Din Ahmed Abu Shelbaya**, Professor of Internal Medicine & Endocrinology, Faculty of Medicine, Ain Shams University for his supervision, guidance and advice throughout this work.

Also, I wish to express my deep gratitude to **Dr. Manal Mohammad Abu-Shady**, Assistant Professor of Internal Medicine & Endocrinology, Faculty of Medicine, Ain Shams university for her good support, continuous supervision and unlimited help during this work.

I also like to express my deepest gratitude to **Dr. Merhan Sami Nasr**, Lecturer of Internal Medicine & Endocrinology, Faculty of Medicine, Ain Shams University, for her continuous supervision, guidance, support and encouragement.

I am also thankful to **Dr. Magdy Abbas Abd El-Aziz**, Counsultant of Biochemistry, Faculty of Medicine, Ain Shams University Hospital.



Yasmeen Abd Almageed Mohamed

List of Contents

	Page
Acknowledgment	--
List of Abbreviations	i
List of Figures	ii
List of Tables	v
Introduction and Aim of The Work	1
Review of Literature	4
Chapter 1 : Diabetes Mellitus	4
Chapter 2 : Diabetic Nephropathy	38
Chapter 3 : Irisin hormone	69
Patients and Methods	93
Results	102
Discussion	121
Summary.....	125
Conclusion	127
Recommendations	128
References	129
Arabic Summary	--

List of Abbreviations

ACE	Angiotensin converting enzyme
ACR	Albumin creatinine ratio
ADA	American diabetic association
AER	Albumin excretion rate
AHEI	Alternate healthy eating index
AMED	Alterante Mediterranean deit score
AMPK	Activated monophosphate protein kinase
ARB	Angiotensin receptor blockers
BAT	Brown adipose tissue
CKD	Chronic kidney disease
CRP	C-Reactive Protein
DKD	Diabetic kidney disease
DNA	Deoxyribonucleic acid
ECM	Extracellular matrix
EE	Energy expenditure
ERK	Extacellular signal regulated kinase
ESRD	End stage renal disease
FN	Fibronectin
Fndc5	Fibronectin domain containing protein 5
GBM	Glomerular basement membrane
GBM	Glomerular basement membrane
GFP	Green fluorescent protein
GFR	Glomerular filtration rate
HLA	Human leukocyte Ag
HNF	Hepatocyte nuclear factor
IDNT	International diabetics and nutritional terminology
IL-15	Interleukin 15
IPF	Insulin Promotor Factor
Lrg1	Leucine rich glycoprotein 1
MESCS	Mouse embryonic stem cells
MODY	Maturity Onset Diabetes Of the young

List of Abbreviations (Cont.)

PGC1 α	Peroxisome proliferator-activated receptor-8 coactivator 1 alpha
PPAR α	Peroxisome proliferator activated receptor α
RENAAL	Reduction in endpoints with angiotensin antagonist losartan
SHARP	Study of heart and renal protection
STAT	Signal transducer and activator of transcription
TBM	Tubular basement membrane
TIMP4	Tissue inhibitor of metalloproteinases 4
tRNA	Transfer ribonucleic acid
UAE	Urinary albumin excretion
UCP1	Uncoupling protein 1
VEGF β	Vascular endothelial growth factor β
WAT	White adipose tissue

List of Figures

Fig.	Title	Page
1	Diagnosis of diabetes mellitus	14
2	Clinical features of DR by fundus examination	26
3	Major key factors involved in the pathogenesis of diabetic retinopathy	28
4	Schematic diagram showing types of diabetic neuropathy (A) Distal symmetrical peripheral neuropathy, (B) proximal neuropathy, (C) cranial and truncal neuropathy, and (D) mononeuropathy multiplex	32
5	The molecular mechanism involved in induction and progression of diabetic nephropathy	46
6	Schematic diagram of the interrelationship of the glomerulus, the podocyte, the pedicels, and the basal laminae	49
7	Mediators of podocyte injury in DKD. Several molecular pathways are known to contribute to podocyte injury in DKD	51
8	Light microscopy photographs of glomeruli in sequential kidney biopsies performed at baseline and after 5 and 10 years of follow-up in a patient with longstanding normoalbuminuric type 1 diabetes with progressive mesangial expansion and kidney function deterioration.	56
9	Electron microscopy photographs of mesangial area in a normal control subject (A) and in a patient with type 1 diabetes (B).	57
10	Light microscopy photographs of glomeruli from type 1 (A) and type 2 (B through D) diabetic patients.	58
11	Crystal structure of irisin.	71
12	Natural β -sheet protein	72

List of Figures (Cont.)

Fig.	Title	Page
13	Structure of the irisin dimer	73
14	Irisin dimer contacts and mutagenesis experiments.	74
15	The myocyte-adipocyte connection.	75
16	Gender distribution in all studied groups	103
17	Comparison between diabetic group (group1 and group2) and group 3 as regard irisin	104
18	Systolic blood pressure in different studied groups	108
19	Diastolic blood pressure in all studied groups	108
20	BMI in different studied groups	109
21	Serum creatinine in different studied groups	109
22	BUN in different studied groups	110
23	Irisin in different studied groups	111
24	Comparison between patients (Group1 and Group2) as regard duration of diabetes	111
25	Comparison between group1 and group2 as regard HbA1c	112
26	Comparison between group1 and group2 as regard albumin creatinine ratio	112
27	Comparison between patients with different ranges of albuminuria as regard serum Irisin	114
28	Correlation between irisin and systolic blood pressure	116
29	Correlation between irisin and diastolic blood pressure	116
30	Correlation between irisin and BMI	117
31	Correlation between irisin and HbA1c	117
32	Correlation between irisin and creatinine	118
33	Correlation between irisin and duration of diabetes	118
34	Correlation between irisin and alb/creat	119

List of Tables

Table	Title	Page
I	Prevalence of diabetes in 2011 and 2030	5
II	Etiological classification of diabetes mellitus	7
III	Comparison between Type I and Type I diabetes mellitus	13
IV	Criteria for the diagnosis of diabetes mellitus	15
V	Clinical manifestations of autonomic diabetic neuropathy	32
VI	Definitions of Abnormal Albumin Excretion	42
VII	Classification Of Diabetic Nephropathy 2014	43
VIII	Pathology of Diabetic Nephropathy	54
IX	Oral hypoglycemic agents	65
1	Gender distribution between all studied groups	102
2	Comparison between diabetic group (group1 and group2) and group 3 as regard irisin	103
3	Data characteristics of all studied groups regarding demographic and laboratory data	104
4	Data characteristics of group I and II regarding clinical and laboratory data	105
5	Data characteristics of group I and III regarding clinical and laboratory data	106
6	Data characteristics of group II and III regarding clinical and laboratory data	107
7	Comparison between patients with different ranges of albuminuria as regard serum Irisin	113
8	Correlation between irisin and all studied parameters in all groups	114
9	Stepwise Regression Analysis for determination of the most important predictor of serum irisin	120

Introduction

Diabetes is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction, and failure of different organs, especially the eyes, kidneys, nerves, hearts and blood vessels (**Genuth, 2003**).

Diabetic nephropathy is a leading cause of chronic kidney disease and one of the most significant long term complications in terms of morbidity and mortality for individual patients with diabetes. Diabetes is responsible for 30-40% of all end stage renal disease (**ESRD**) cases (**Burney Bo et al., 2009**).

In January 2012, Bostrom and colleagues identified a new muscle tissue secreted peptide, which they named IRISIN (referring to Greek messenger Goddess IRIS, to highlight its role as a messenger that comes from skeletal muscle to other parts of the body (**Bostrom, 2012**)).

Irisin hormone is normally present as part of a larger protein Fibronectin domain-containing protein 5 (FNDC5) in a muscle cell's outer membrane, where it lies dormant and inactive. Exercise (and other unknown factors) cause this protein to be split, releasing irisin, which exits the muscle cell to other cells of the body causing conversion of some white fat cells to brown fat cells and islet cells of pancreas which are told to produce more insulin (**Aggarwal, 2012**).

There is controversy concerning irisin level in plasma that it is reduced in Type 2 Diabetic (T2D) by 50%. Some studies found that serum irisin levels were decreased in T2D patients and inversely associated with newly diagnosed T2D, suggesting that irisin may play a role in glucose intolerance

and T2D in presence of insulin resistance (**choi, 2013**). Although it is also reported that irisin hormone expression is not related to diabetes status in humans (**Timmons, 2012**).

Preliminary studies suggest that irisin is decreased in Type 2 diabetic patients with renal insufficiency (GFR<60ml/min/1.73m (2) (**Liu et al., 2014**).

However no studies evaluate irisin in type2 diabetic patients with Microalbuminuria.



Aim of The Work

The aim of this work is to study Irisin Hormone level in Type 2 diabetic patient. Also, to study the relation between Irisin Hormone level and diabetic nephropathy.

Chapter (I)

Diabetes mellitus

Definition of diabetes mellitus:

Diabetes is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both (**American Diabetic Association, 2014**).

Epidemiology:

Over the past three decades, the number of people with diabetes mellitus has more than doubled globally, making it one of the most important public health challenges to all nations. Type 2 diabetes mellitus and prediabetes are increasingly observed among children, adolescents and younger adults (**Chen et al., 2011**).

Diabetes can be found in every country in the world and without effective prevention and management programmes the burden will continue to increase globally. Type 2 diabetes makes up about 85 to 95% of all diabetes in high-income countries and may account for an even higher percentage in low- and middle-income countries. Type 2 diabetes is now a common and serious global health problem, which, for most countries, has developed together with rapid cultural and social changes, ageing populations, increasing urbanisation, dietary changes, reduced physical activity, and other unhealthy behaviours (**World Health Organization, 1994**).

Rates of diabetes have increased markedly over the last 50 years in parallel with obesity. As of 2010 there are approximately 285 million people with the disease compared to around 30 million in 1985 (**Fasanmade et al., 2008**).

The global burden:

- **366 million** people have diabetes in 2011; by 2030 this will have risen to **552 million**.

- The number of people with type 2 diabetes is **increasing** in every country.
 - **80%** of people with diabetes live in **low- and middle-income countries**.
 - The **greatest number** of people with diabetes are between **40 to 59** years of age.
 - **183 million** people (50%) with diabetes are **undiagnosed**
 - Diabetes caused **4.6 million deaths** in 2011.
 - Diabetes caused at least **USD 465 billion dollars** in healthcare expenditures in 2011; **11% of total healthcare expenditures** in adults (20-79 years).
 - **78.000 children** develop **type 1 diabetes** every year.
- (IDF, 2011)

Table (I): Prevelence of diabetes in 2011 and 2030

Year	Country/territory	Millions
2011	1- China	90.0
	2- India	61.30
	3- United States of America	23.70
	4- Russian Fedration	12.60
	5- Brazil	12.40
	6- Japan	10.70
	7- Mexico	10.30
	8- Bengladesh	8.40
	9- Egypt	7.30
	10- Indonesia	7.30
2030	1- China	129.70
	2- India	101.20
	3- United states of america	29.60
	4- Brazil	19.60
	5- Bengladesh	16.80
	6- Mexico	16.40
	7- Russian federation	14.10
	8- Egypt	12.40
	9- Indonesia	11.80
	10- Pakistan	11.40

(IDF Diabetes Atlas, 2011)

Pathogenesis:

Several pathogenic processes are involved in the development of diabetes. These range from autoimmune destruction of the pancreatic β -cells with consequent insulin deficiency to abnormalities that result in resistance to insulin action. The basis of the abnormalities in carbohydrate, fat, and protein metabolism in diabetes is deficient action of insulin on target tissues. Deficient insulin action results from inadequate insulin secretion and/or diminished tissue responses to insulin at one or more points in the complex pathways of hormone action. Impairment of insulin secretion and defects in insulin action frequently coexist in the same patient, and it is often unclear which abnormality, if either alone, is the primary cause of the hyperglycemia. A degree of hyperglycemia sufficient to cause pathologic and functional changes in various target tissues, but without clinical symptoms, may be present for a long period of time before diabetes is detected. During this asymptomatic period, it is possible to demonstrate an abnormality in carbohydrate metabolism by measurement of plasma glucose in the fasting state or after a challenge with an oral glucose load or by A1C (**Geiss et al., 2006**).

Symptoms of DM:

Symptoms of marked hyperglycemia include polyuria, polydipsia, weight loss, sometimes with polyphagia, and blurred vision. Impairment of growth and susceptibility to certain infections may also accompany chronic hyperglycemia. Acute, life-threatening consequences of uncontrolled diabetes are hyperglycemia with ketoacidosis or the nonketotic hyperosmolar syndrome (**Cooke and Plotinck, 2008**).

Classification of diabetes mellitus:

This classification has now replaced the earlier clinical classification into insulin dependent DM (IDDM) and non Insulin dependant DM (NIDDM) which was based on the need for insulin treatment at diagnosis (**Mirghani, 2012**).